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ABSTRACT
This report describes the case of a 39-year-old male patient who presented to 
the emergency room with complaints of impaired balance, diplopia, and nasal 
voice. The patient had a history of upper respiratory tract infection. The initial 
physical examination revealed ataxia, ophthalmoplegia, and areflexia, which 
are consistent with the classic triad of Miller Fisher syndrome, considered 
a benign variant of Guillain-Barré syndrome. The patient developed 
peripheral facial paralysis during hospitalization. He underwent a treatment 
with immunoglobulin for five days, resulting in near complete resolution of 
the ataxia. However, the ophthalmoplegia and areflexia persisted. He was 
discharged to outpatient follow-up.
Keywords: Miller Fisher syndrome; Ataxia; Ophthalmoplegia; GQ1b ganglioside [Supplementary 
concept]; Facial nerve.
CASE REPORT
A previously healthy 39-year-old male 
patient of Asian ancestry first presented to the 
emergency room with a four-day history of dizziness 
and impaired balance, he felt as if he were “drunk”. 
He was discharged after symptomatic treatment. 
The patient returned two days later with complaints 
of diplopia, nasal voice, and persistence of the 
previous symptoms, and therefore he was admitted 
for clinical investigation. He reported that two weeks 
before the onset of those symptoms, he had had 
“the flu” with rhinorrhea, nasal obstruction, and 
headache.
Physical examination at admission showed 
a well-being patient, conscious and alert, afebrile 
and acyanotic. He had no jaundice, was well 
hydrated, eupneic, and the blood pressure was 
normal. The cardiovascular, respiratory, and 
digestive systems showed no abnormalities on 
examination. Neurological examination findings 
were as follows: a Glasgow Coma Scale score 
of 15; no signs of meningeal irritation; a negative 
Romberg sign; “drunken sailor” gait; finger-to-nose 
maneuver with intention tremor, especially on the 
left side; blepharoptosis, especially on the right; 
bilateral mydriasis with absence of photomotor 
and consensual reflexes; paresis of the III, IV and 
VI cranial nerves determining incapacity of the 
horizontal and vertical eye movements as well as 
arreflexia of the deep reflexes.
The initial laboratory work up showed 
leukocytosis, on total blood cell count, with no shift 
to the left; normal electrolyte and renal function 
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peripheral nervous system, and, in the literature, 
there remains controversy regarding the involvement 
of the central nervous system (CNS).1
A review published by Berlit in 1992 showed 
that there have been reports of pathological findings 
on ancillary tests such as electroencephalography 
(38 cases), brain CT (8 cases), and magnetic 
resonance imaging of the brain (2 cases), thereby 
providing possible evidence of involvement of the 
CNS in Miller Fisher syndrome.1
Miller Fisher syndrome is a rare disease. 
The exact incidence of the syndrome is not known 
and can vary among geographic areas. In a study 
conducted in the southwestern region of the 
Netherlands, the incidence was estimated to be 
approximately 1-2 cases per million population per 
year.2 Various authors have reported an annual 
incidence of 0.9 per million population, showing 
that the disease affects patients between 13 and 
78 years of age, being more common among 
patients in their 40s, and more prevalent in males 
than in females, at a ratio of 2:1.3 In addition, the 
incidence of the syndrome appears to be higher 
among Asians.4
The triad of ataxia, areflexia, and 
ophthalmoplegia as a variant of Guillain-Barré 
syndrome was first described in 1932 by Collier.1 
In 1956, Miller Fisher reported three patients 
with ataxia, areflexia, and ophthalmoplegia as a 
separate entity.1 Since then, 223 cases of Miller 
Fisher syndrome have been reported.1
Studies show that approximately 70% of 
cases are preceded (by 10 days, on average) 
by respiratory or intestinal tract infection1,5-7, as 
in the case described here, in which the patient 
had upper airway infection two weeks before the 
onset of symptoms. The infectious agents most 
commonly involved include Campylobacter jejuni, 
Haemophilus influenzae, Epstein-Barr virus, and 
cytomegalovirus. In some patients, however, no 
association with infection is found.6,8
Snyder et al. demonstrated the association 
between Miller Fisher syndrome and the following 
infectious agents: Campylobacter jejuni, in 21%; 
Haemophilus influenzae, in 8%; cytomegalovirus, 
in 4%; and Mycoplasma pneumoniae; in 3%.8 
Less commonly found agents included Epstein-
Barr virus, Coxiella burnetii, Pasteurella multocida, 
Helicobacter pylori, Aspergillus spp., and varicella 
determinations. Because the working diagnosis 
was brainstem encephalitis, CSF was collected for 
analysis, which showed the following: a clear and 
colorless fluid with 1 cell/mm3, 1 red blood cell/
mm3, a protein level of 45 mg/dl, a glucose level of 
66 mg/dl, and a lactate level of 14 mg/dl. Pandy’s 
reaction was negative, the India ink test was 
negative, and the adenosine deaminase level was 
within the normal range. A microbiological analysis 
showed no bacterial growth.
The findings on non-contrast enhanced 
computed tomography (CT) and CT angiography of 
the skull were normal, ruling out the hypothesis of 
venous sinus thrombosis.
Taking into account the clinical data 
(anamnesis), together with the neurological findings 
characterizing the triad of ataxia, ophthalmoplegia, 
and areflexia following an episode of upper 
respiratory tract infection, and considering that 
physical examination and laboratory tests revealed 
no other abnormalities, the Miller Fisher syndrome 
was considered as the final diagnosis.
The patient developed peripheral facial 
paralysis during hospitalization and underwent 
5 days of treatment with intravenous human 
immunoglobulin. The ataxia lessened significantly, 
as well as the motor coordination improved. In 
addition, there was complete resolution of the 
bilateral mydriasis and bilateral recovery of the 
photomotor reflex. However, the areflexia in upper 
and lower limbs persisted at hospital discharge, 
as did the bilateral ophthalmoplegia. The patient 
tested positive for anti-GQ1b antibodies, resulting in 
1/6400 (reference value < 1/100). The patient was 
discharged with the recommendation for specialized 
outpatient follow-up.
DISCUSSION
Miller Fisher syndrome is considered 
a benign variant of Guillain-Barré syndrome, 
which manifests with the clinical triad of ataxia, 
areflexia, and ophthalmoplegia. However, in order 
to diagnose Miller Fisher syndrome, not all signs 
of the clinical triad need to be present, which can 
often make the diagnosis difficult. Miller Fisher 
syndrome is a multifocal neuropathy, classified as 
an acute, autoimmune, inflammatory demyelinating 
disease that primarily affects peripheral neurons. 
The syndrome was first described as affecting the 
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The involvement of cranial nerves other than the 
oculomotor was reported in 127 cases1: facial 
nerve (in 45.7%); glossopharyngeal and vagus 
nerve (in 39.9%); and hypoglossal nerve (in 13%). 
Other less common signs and symptoms include 
blepharoptosis, photophobia, dysphagia, and 
headache.8 The pathogenesis of ataxia has yet 
to be determined and fully understood. Central 
and peripheral mechanisms might be involved, 
comprising a proprioceptive and/or cerebellar 
component. Further studies would be needed to 
come to a conclusion. Controversies regarding this 
issue persist in the literature reviewed, because 
immunohistochemical studies have shown that anti-
GQ1b antibodies, which are involved in this entity, 
stain sensory neurons in the dorsal root ganglion and 
a population of cerebellar neurons. Therefore, it is 
possible that the two mechanisms are associated.12
In addition to the classic triad of ataxia, 
ophthalmoplegia, and areflexia, the clinical 
presentation of Miller Fisher syndrome includes the 
involvement of other cranial nerves, with the facial 
nerve being the most commonly affected nerve, as 
observed in this case. Chief among spared cranial 
nerves is the optic nerve, which is rarely affected.12
The diagnosis is based on the clinical 
presentation, combined with testing of the CSF, 
which shows characteristic protein-cytological 
dissociation and high levels of anti-GQ1b IgG 
antibodies determined by ELISA. It should be borne 
in mind that the CSF can be normal, especially in 
the initial phase of the disease, which does not rule 
out the diagnosis, as in the case reported here.
In a review of the literature on Miller Fisher 
syndrome conducted in 1992, Berlit et al. found 
high protein levels in the CSF of 134 patients 
(64.4% of the cases), whereas, in 56 patients, the 
CSF was normal.1 Magnetic resonance imaging 
of the brain shows no specific lesions.7 Common 
electroneuromyography findings include increased 
distal latency and action potential abnormalities of 
the sensory nerves.12
Similarly to imaging tests, CSF testing is also 
performed to exclude other diseases. The differential 
diagnosis with other CNS pathological processes, 
such as infectious processes, granulomatous 
processes, demyelinating diseases, intoxications, 
and vasculitis, should be considered in the clinical 
investigation.12
zoster virus.8 Cases of Miller Fisher syndrome after 
influenza vaccination have also been documented.8
Recently, there have been published 
reports of five cases of variants of Guillain-Barré 
syndrome that occurred four weeks after H1N1 
vaccination during the 2010 and 2011 campaigns. 
In those cases, there was no evidence of other 
possible etiologies to explain the clinical course 
characterized by ataxia, areflexia, dysautonomia, 
sphincter dysfunction, and protein-cytological 
dissociation in the CSF. One patient developed 
the classic Miller Fisher syndrome after H1N1 
vaccination. All those patients were treated with 
immunoglobulin, with variable responses. It was 
concluded that administration of the vaccine could 
be associated with the development of variants of 
Guillain-Barré syndrome, and further studies are 
required for confirmation.9
Infectious agents are believed to contribute 
to the formation of anti-GQ1b IgG antibodies, 
which were first credited as determining factors 
in the pathogenesis of Miller Fisher syndrome 
by Chiba et al.10,11 Studies have shown that, on 
average, more than 90% of patients with Miller 
Fisher syndrome have serum antibodies to the 
GQ1b and GT1a gangliosides.2,10 However, because 
these antibodies can be found in patients with other 
variants of Guillain-Barré syndrome, acute ataxia 
(without ophthalmoplegia), or acute ophthalmoplegia 
(without ataxia), they are not specific to Miller 
Fisher syndrome.2,8 These antibodies are likely 
induced by molecular mimicry during the preceding 
infection and are pathogenic to peripheral nerves. 
In general, these antibodies disappear within 
weeks, concomitantly with clinical improvement.7 
Less commonly, antibodies to other gangliosides, 
including GT1a, GD3, GD1b, and GT1ba, can also 
be detected.2 These antibodies, less commonly, are 
also present in the CSF of patients with Miller Fisher 
syndrome, and, in general, titers of these antibodies 
are much lower in the CSF than in serum.2
Regarding the involvement of the cranial 
nerves, we should bear in mind that the oculomotor 
nerve fibers are rich in GQ1b antigen. That might 
explain the involvement of these fibers in Miller 
Fisher syndrome and the observed high frequency 
of ophthalmoplegia with serum positivity to this 
antigen in patients with Miller Fisher syndrome.12
The most common initial symptom is 
diplopia (in 38.6%), followed by gait disorders (in 
20.6%). Areflexia is present in 81.6% of cases. 
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The treatment of Miller Fisher syndrome is 
based on support measures and monitoring of vital 
signs. Rarely, the disease evolves to a stage that 
requires intensive care or mechanical ventilation, 
which is more common in Guillain-Barré syndrome. 
According to the literature, the use of intravenous 
immunoglobulin or plasmapheresis shows 
controversial results. In most patients receiving 
either treatment, recovery is more rapid, when 
compared with those not receiving any treatment, 
but this difference is not statistically significant.13-15 
Complete recovery occurs in 80% of patients within 
one to two years. A permanent deficit is seen in 
5-10% of patients, and mortality ranges from 2 to 
3%, being caused by secondary infections.7,16-18 
Recurrence of the syndrome has been reported in 
seven cases.1
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